Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Noble Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$710,006

111 payments

Through program year 2025, Noble Clinical Research is reported as receiving $710,006 in research payments, across 111 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $103,012 33
2024 Research $186,939 16
2023 Research $191,036 22
2022 Research $106,619 30
2021 Research $29,437 6
2020 Research $4,796 2
2019 Research $88,167 2

Breakdown

Who paid Research payments · program years 2019–2025
  1. Sanofi US Services Inc. $515,655 51 payments
  2. Flexion Therapeutics, Inc. $92,963 4 payments
  3. AstraZeneca Pharmaceuticals LP $19,964 1 payment
  4. AstraZeneca UK Limited $19,060 2 payments
  5. Pfizer Inc. $18,688 39 payments
  6. Genzyme Corporation $17,900 1 payment
  7. GlaxoSmithKline, LLC. $13,408 1 payment
  8. Bayer HealthCare Pharmaceuticals Inc. $8,250 2 payments
  9. Boehringer Ingelheim Canada Ltd.Ltee $3,607 2 payments
  10. Moderna TX, Inc. $372 6 payments
Studies the money was for Research payments · program years 2019–2025
  1. Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) $422,071 36 payments
  2. A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies $93,585 15 payments
  3. A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of FX006 in Patients with Hip Osteoarthritis $51,761 1 payment
  4. Study to Evaluate a Procedure for Intra-articular Injection of FX006 in Patients With Osteoarthritis of the Hip $36,406 1 payment
  5. A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA) $19,964 1 payment
  6. BRISOTE A Multicentre Randomised DoubleBlind Parallel Group ActiveControlled Phase 3b Study to Evaluate the Efficacy and Safety of Benralizumab 30 mg SC in Eosinophilic Asthma Patients Uncontrolled on Medium Dose Inhaled Corticosteroid Plus Long acting 2 Agonist $19,060 2 payments
  7. A Phase 3, multicenter, randomized, double-bline, placebo controlled, parallel-group study with an open-label period and long-term extension to assess the efficacy and safety of rilzabrutinib in participants with warm autoimmune hemolytic anemia (WAIHA) $17,900 1 payment
  8. A Phase 3A, Open-Label, Randomized, Controlled Study to Evaluate the I $13,408 1 payment
  9. A Phase 12 Randomized Study to Evaluate the Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza in Healthy Individuals $8,580 1 payment
  10. A Phase 3 Randomized Doubleblind Placebocontrolled Clinical Study Evaluating the Safety Tolerability Immunogenicity and Efficacy of A Variantadapted Bnt162b2 Vaccine in Healthy Participants 50 Through 64 Years of Age $8,532 20 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record